SAMAALB Trademark

Trademark Overview


On Tuesday, October 3, 2023, a trademark application was filed for SAMAALB with the United States Patent and Trademark Office. The USPTO has given the SAMAALB trademark a serial number of 79384995. The federal status of this trademark filing is REGISTERED as of Tuesday, May 14, 2024. This trademark is owned by Novartis AG. The SAMAALB trademark is filed in the Pharmaceutical Products category with the following description:

Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the p...
samaalb

General Information


Serial Number79384995
Word MarkSAMAALB
Filing DateTuesday, October 3, 2023
Status700 - REGISTERED
Status DateTuesday, May 14, 2024
Registration Number7383571
Registration DateTuesday, May 14, 2024
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, February 27, 2024

Trademark Statements


Goods and ServicesAnti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, December 15, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameNovartis AG
Party Type30 - Original Registrant
Legal Entity Type25 - NOT AVAILABLE
AddressCH

Party NameNovartis AG
Party Type20 - Owner at Publication
Legal Entity Type25 - NOT AVAILABLE
AddressCH

Party NameNovartis AG
Party Type10 - Original Applicant
Legal Entity Type25 - NOT AVAILABLE
AddressCH

Trademark Events


Event DateEvent Description
Thursday, December 7, 2023SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB
Tuesday, December 12, 2023LIMITATION FROM ORIGINAL APPLICATION ENTERED
Friday, December 15, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, December 19, 2023APPLICATION FILING RECEIPT MAILED
Tuesday, January 2, 2024TEAS CHANGE OF OWNER ADDRESS RECEIVED
Tuesday, January 2, 2024APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Tuesday, January 2, 2024TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, January 2, 2024ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, January 2, 2024TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Tuesday, January 2, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, January 18, 2024ASSIGNED TO EXAMINER
Tuesday, January 23, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, February 7, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Wednesday, February 7, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, February 14, 2024NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, February 14, 2024NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Tuesday, February 27, 2024PUBLISHED FOR OPPOSITION
Monday, March 4, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, May 14, 2024REGISTERED-PRINCIPAL REGISTER
Tuesday, May 14, 2024NOTICE OF REGISTRATION CONFIRMATION EMAILED
Thursday, June 13, 2024FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB